FDA May Limit Use of Two COVID Antibody Treatments
MONDAY, Jan. 24, 2022 (healthDay News) — The U.S. Food and Drug Administration may soon curtail the use of two monoclonal antibody treatments that do not appear to work against the highly contagious Omicron variant. The treatments made by Regeneron and Eli Lilly performed well against earlier variants, but onlyContinue Reading